Personal care composition

Abstract

Disclosed is a personal care composition comprising moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1.4:1.

Description

[0001] PERSONAL CARE COMPOSITION

[0002] Field of the Invention

[0003] The present invention relates to a personal care composition comprising moringa oil and coconut oil with a specific weight ratio. Surprisingly, it was found the expression of Heme Oxygenase 1 (HM0X1) gene was synergically upregulated within such ratio.

[0004] Background of the Invention

[0005] Human skin may provide physicochemical protection against environmental insults through its barrier function, mechanical strength and imperviousness to water. It is constantly exposed to harmful environments and extreme conditions, such as ultra-violet radiation, blue light, pollution etc. Such harmful environmental applications may cause excessive generation of reactive oxygen species (ROS) thereby resulting in an oxidative stress condition. Oxidative stress may affect our skin in many ways including signs of premature aging such as wrinkles, fine lines, uneven skin tone.

[0006] Heme Oxygenase 1 (coded by the HM0X1 gene) is known to demonstrate a protective role against oxidative stress. It is an enzyme that catalyzes the degradation of heme to biliverdin a precursor of a powerful antioxidant metabolite, bilirubin which has antioxidant and antiinflammatory properties. Heme Oxygenase 1 , primarily functioning in the catabolism of heme, is a very important cytoprotective enzyme that has antioxidant, anti-inflammatory and anti-apoptotic properties.

[0007] Stimulating HM0X1 gene would, in turn, stimulate the degradation of heme thereby provide antiaging, anti-oxidation and anti- inflammatory benefits. Human skin is also a place where inflammation, oxidative stress and cellular damage occurs regularly.

[0008] Therefore, the present inventors have recognized there is a need to develop a personal care composition which is capable of improving the expression of HM0X1 gene and developed a personal care composition comprising moringa oil and coconut oil, it was surprisingly found that the expression of HM0X1 gene is capable of significantly upregulated when the weight ratio of the moringa oil to the coconut oil is at least 1.4:1. Summary of the Invention

[0009] In a first aspect, the present invention is directed to a personal care composition comprising moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1.4:1.

[0010] In a second aspect, the present invention is directed to a method for providing antioxidant, antiinflammatory, anti-apoptotic and / or anti-aging benefit; reducing oxidative stress; and / or upregulating the expression of Heme Oxygenase 1 gene, comprising a step of topically applying to the skin the composition of the present invention.

[0011] In a third aspect, the present invention is directed to use of the composition of the present invention for providing antioxidant, anti-inflammatory, anti-apoptotic benefit; reducing oxidative stress; and / or upregulating the expression of Heme Oxygenase 1 gene.

[0012] All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.

[0013] Detailed Description of the Invention

[0014] Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and / or use may optionally be understood as modified by the word “about”.

[0015] All amounts are by weight of the composition, unless otherwise specified.

[0016] It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.

[0017] For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of’. In other words, the listed steps or options need not be exhaustive.

[0018] The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy. Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.

[0019] Typically, the moringa oil comprises or is moringa seed oil. Preferably, the moringa oil is extracted from seeds of at least one of Moringa oleifera, Moringa pterygosperma, Moringa peregrina, Moringa concanensis or Moringa drouhardii. The seeds of moringa are characterized by the presence of an oil whose content could vary from 10 to 80%, preferably 20 to 60% according to the species and maturity of the seeds. For the species Moringa oleifera, the contents of oil range 15 to 45%, preferably from 21 to 34% in the seeds of Moringa oleifera. For sake of clarity, the moringa oil is typically liquid at 25°C and atmospheric pressure.

[0020] Preferably, the moringa oil is extracted from the seeds of Moringa Oleifera. Preferably the moringa oil is extracted by cold-pressing. Preferably, the moringa oil comprises C18-24 fatty acid, more preferably the moringa oil comprises C18-22 fatty acid and preferably even more preferably the moringa oil comprises behenic acid.

[0021] Preferably, the moringa oil is present in amount of 0.0001 to 10%, more preferably 0.005 to 5%, even more preferably 0.015 to 2% and still even more preferably 0.03 to 0.6%, and most preferably 0.06 to 0.3% by weight of the composition.

[0022] Preferably, the moringa seed oil is present in amount of 0.0001 to 10%, more preferably 0.005 to 5%, even more preferably 0.015 to 2% and still even more preferably 0.03 to 0.6%, and most preferably 0.06 to 0.3% by weight of the composition.

[0023] Coconut oil is an edible extract from the kernel or meat of mature coconuts harvest from the coconut palm. Preferably, the coconut oil comprises up to 85% of saturated fatty acid by weight of the coconut oil. The saturated fatty acid may comprise up to 48% of lauric acid by weight of the coconut oil.

[0024] The coconut oil may be produced by a dry process or a wet process. Preferably the coconut oil is produced by cold pressing. The coconut oil may be refined, hydrogenated, and / or fractionated. In certain embodiments, the coconut oil is unrefined coconut oil. Preferably, the coconut oil is not refined, bleached, and / or deodorized. Additionally, the unrefined coconut oil is not hydrogenated or fractionated.

[0025] Preferably, the the weight ratio of the moringa oil to the coconut oil is in the range of is 1.4:1 to 200:1 , more preferably 1.4:1 to 50:1 , even more preferably 1.4:1 to 20:1 and most preferably 1.4:1 to 15:1. In certain embodiments, the weight ratio of the moringa oil to the coconut oil is preferably in the range of is 2.8:1 to 200:1 , more preferably 2.8:1 to 50:1 , even more preferably 2.8:1 to 15:1. In particularly preferred embodiments, the weight ratio of the moringa oil to the coconut oil is preferably in the range of is 2.8:1 to 8:1 and more preferably 2.8:1 to 6:1.

[0026] Preferably, the the weight ratio of the moringa seed oil to the coconut oil is in the range of is 1.4: 1 to 200:1 , more preferably 1.4:1 to 50:1 , even more preferably 1.4:1 to 20:1 and most preferably 1.4:1 to 15:1. In certain embodiments, the weight ratio of the moringa seed oil to the coconut oil is preferably in the range of is 2.8:1 to 200:1 , more preferably 2.8:1 to 50:1 , even more preferably 2.8:1 to 15:1. In particularly preferred embodiments, the weight ratio of the moringa seed oil to the coconut oil is preferably in the range of is 2.8:1 to 8:1 and more preferably 2.8:1 to 6:1.

[0027] Preferably, the coconut oil is present in amount of 0.00001 to 10%, more preferably 0.0001 to 5%, even more preferably 0.001 to 2% and still even more preferably 0.003 to 0.6%, and most preferably 0.01 to 0.2% by weight of the composition.

[0028] The composition preferably comprises a cleansing surfactant. More than one cleansing surfactant may be included in the composition. The cleaning surfactant may be chosen from soap, non-soap anionic, cationic, non-ionic, amphoteric surfactant and mixtures thereof. Many suitable surfaceactive compounds are available and are fully described in the literature, for example, in "Surface- Active Agents and Detergents", Volumes I and II, by Schwartz, Perry and Berch. The preferred surface-active compounds that can be used are soaps, non-soap anionic, non-ionic surfactant, amphoteric surfactant or a mixture thereof.

[0029] Suitable non-soap anionic surfactants include linear alkylbenzene sulphonate, primary and secondary alkyl sulphates, particularly Cs to C15 primary alkyl sulphates; alkyl ether sulphates; olefin sulphonates; alkyl xylene sulphonates; dialkyl sulphosuccinates; fatty acid ester sulphonates; or a mixture thereof. Sodium salts are generally preferred. Most preferred non-soap anionic surfactant are linear alkylbenzene sulphonate, particularly linear alkylbenzene sulphonates having an alkyl chain length of from Cs to C15. It is preferred if the level of linear alkylbenzene sulphonate is from 0 wt% to 30 wt%, more preferably from 1 wt% to 25 wt%, most preferably from 2 wt% to 15 wt%, by weight of the total composition.

[0030] Nonionic surfactants that may be used include the primary and secondary alcohol ethoxylates, especially the Cs to C20 aliphatic alcohols ethoxylated with an average of from 1 to 20 moles of ethylene oxide per mole of alcohol, and more especially the C10 to C15 primary and secondary aliphatic alcohols ethoxylated with an average of from 1 to 10 moles of ethylene oxide per mole of alcohol. Non ethoxylated nonionic surfactants include alkylpolyglycosides, glycerol monoethers, and polyhydroxyamides (glucamide). It is preferred if the level of non-ionic surfactant is from 0 wt% to 30 wt%, preferably from 1 wt% to 25 wt%, most preferably from 2 wt% to 15 wt%, by weight of a fully formulated composition comprising the microcapsules of the invention.

[0031] Suitable amphoteric surfactants preferably are betaine surfactants. Examples of suitable amphoteric surfactants include, but are not limited to, alkyl betaines, alkylamido betaines, alkyl sulfobetaines, alkyl sultaines and alkylamido sultaines; preferably, those having 8 to about 18 carbons in the alkyl and acyl group. It is preferred that the amount of the amphoteric surfactant is 0 to 20 wt%, more preferably from 1 to 10 wt%, by weight of the composition.

[0032] It is also possible to include certain mono-alkyl cationic surfactants. Cationic surfactants that may be used include quaternary ammonium salts of the general formula R1R2R3R4N+X' wherein the R groups are long or short hydrocarbon chains, typically alkyl, hydroxyalkyl or ethoxylated alkyl groups, and X is a counter-ion (for example, compounds in which R1is a C8-C22 alkyl group, preferably a Cs-C or C12-C14 alkyl group, R2is a methyl group, and R3and R4, which may be the same or different, are methyl or hydroxyethyl groups); and cationic esters (for example, choline esters).

[0033] Water-insoluble skin benefit agents may also be formulated into the compositions as conditioners and moisturizers. Examples include silicone oils; hydrocarbons such as liquid paraffins, petrolatum, microcrystalline wax, and mineral oil; and vegetable triglycerides such as sunflower seed and cottonseed oils.

[0034] Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Preferably the composition comprises acrylic polymers, preferably homopolymers and copolymers of acrylic and methacrylic acids. Among the acrylic polymer thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.

[0035] Preservatives can desirably be incorporated into the compositions of this invention to protect against the growth of potentially harmful microorganisms. Suitable traditional preservatives for compositions of this invention are alkyl esters of para-hydroxybenzoic acid. Other preservatives which have more recently come into use include hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives are phenoxyethanol, methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroacetate and benzyl alcohol. The preservatives should be selected having regard for the use of the composition and possible incompatabilities between the preservatives and other ingredients. Preservatives are preferably employed in amounts ranging from 0.01 % to 2% by weight of the composition.

[0036] A variety of other optional materials may be formulated into the compositions. These may include: antimicrobials such as 2-hydroxy-4,2’,4’-trichlorodiphenylether (triclosan), 2,6-dimethyl-4- hydroxychlorobenzene, and 3,4,4’-trichlorocarbanilide; scrub and exfoliating particles such as polyethylene and silica or alumina; cooling agents such as menthol; skin calming agents such as aloe vera; and colorants.

[0037] In addition, the compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene / Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.

[0038] The composition may comprise water in amount of 10 to 90% by weight of the composition, more preferably from 20 to 85%, even more preferably from 25 to 78%, most preferably from 32 to 65% by weight of the composition. Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s’1. Preferably, the composition is in the form of fluid at atmospheric pressure and 25 degrees C.

[0039] Preferably, the personal care composition is a skin care composition. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.

[0040] Preferably the method is non-therapeutic. Preferably the use is non-therapeutic. The term non- therapeutic means for cosmetic purposes and not curative or therapeutic purposes.

[0041] The present invention also provides a composition comprising a moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1 .4: 1 for use in providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefit; reducing oxidative stress; and / or upregulating the expression of Heme Oxygenase 1 gene.

[0042] The present invention also provides use of a combination of moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1 .4:1 for use in the manufacture of a medicament for for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefit; reducing oxidative stress; and / or upregulating the expression of Heme Oxygenase 1 gene.

[0043] Preferably, the composition is capable of upregulating the expression of expression of Heme Oxygenase 1 (HM0X1) gene by at least 1.9 fold change, more preferably 1.9 to 6 and even more preferably 2 to 5, still even more preferably 2.7 to 4.5 and most preferably 3.3 to 4 fold change, typically in comparison to personal care composition comprising neither moringa oil nor coconut oil.

[0044] The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.

[0045] Examples

[0046] Example 1 This example demonstrates the preparation of personal care compositions containing moringa seed oil and coconut oil.

[0047] Table 1

[0048] *The level refers to the level of the raw material, in weight percentage. a: Moringa refined seed oil, procured from Givaudan, France. b: Coconut oil from Cargill BV, the Netherlands.

[0049] A series of personal care composition was prepared according to Table 1 by following standard procedure.

[0050] Example 2

[0051] This example demonstrates the performance of upregulating the expression of HM0X1 gene by different personal care compositions.

[0052] ArchSkin living skin equivalent (LSE), is a 3D reconstructed human epidermis model with Chinese human keratinocytes through air-liquid interface culture in a defined serum free medium, supplied by Archgene (Shanghai, China). Squalene monohydroperoxide (SQOOH), a stress surrogate, was prepared in house, by subjecting squalene to solar irradiation in the presence of a sensitizer.

[0053] The samples were diluted in phosphate buffered saline (PBS) at volume ratio of 1 :1. The SQOOH was diluted using squalene to be 1 % by weight. 10 pL of diluted SQOOH was applied topically on the LSEs and left for 30 seconds. Then, the LSEs were topical treated by 10pL of the diluted samples for another 30 seconds and gently rinsed by 20mL PBS. After 24 hours, the tissues were collected for gene expression analysis.

[0054] The extracted RNA was quantified using Nanodrop spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate the template cDNA using the Evo M-MLV RT Premix for qPCR (Accurate Biotechnology, Cat: AG11706) according to manufacturer’s protocol. Gene expression of HM0X1 gene was analyzed by polymerase chain reaction (PCR) using SYBR® Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, AG11701). The actin beta (ACTS) gene was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to ACTB gene. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold changes in gene expression of HM0X1.

[0055] The results were summarised in Table 2.

[0056] Table 2 a: significantly better than any one of sample A, B, or C (p<0.05) b: significantly better than sample 3 (p<0.05) c: significantly better than sample 1 (p<0.05)

[0057] It is evident from the data in Table 1 that samples 1 , 2 and 3 are capable of significantly elevating the expression of HM0X1 gene than that of samples A, B, or C. Sample 1 performs significantly better in elevating the expression of HM0X1 gene than sample 3 and sample 2 performs significantly better in elevating the expression of HM0X1 gene than both samples 1 and 3.

Claims

Claims1. A personal care composition comprising a moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1.4:1.

2. The composition as claimed in claim 1 wherein the moringa oil comprises or is moringa seed oil.

3. The composition as claimed in claim 2 wherein the moringa oil is extracted from the seeds of Moringa Oleifera.

4. The composition as claimed in any one of the preceding claims wherein the moringa oil is present in amount of 0.0001 to 10%, more preferably 0.015 to 2% by weight of the composition.

5. The composition as claimed in any one of the preceding claims wherein the coconut oil is unrefined coconut oil.

6. The composition as claimed in any one of the preceding claims wherein the coconut oil is not hydrogenated or fractionated.

7. The composition as claimed in any one of the preceding claims wherein the weight ratio of the moringa oil to the coconut oil is in the range of is 1.4:1 to 50: 1 , preferably 1.4:1 to 15:1, more preferably 2.8:1 to 8:1.

8. The composition as claimed in any one of the preceding claims wherein the weight ratio of the moringa seed oil to the coconut oil is in the range of is 1.4:1 to 50:1, preferably 1.4:1 to 15:1 , more preferably 2.8:1 to 8:1.

9. The composition as claimed in any one of the preceding claims wherein the coconut oil is present in amount of 0.00001 to 10%, preferably 0.003 to 0.6% by weight of the composition.

10. The composition according to any one of the preceding claims wherein the composition comprises water in amount of 25 to 78% by weight of the composition.

11. A method for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefit; reducing oxidative stress; and / or upregulating the expression of Heme Oxygenase 1 gene, comprising a step of topically applying to the skin the composition as claimed in any one of the preceding claims.

12. Use of for the composition as claimed in any one of the preceding claims for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefit; reducing oxidative stress; and / or upregulating the expression of Heme Oxygenase 1 gene.

Images